Drug Profile
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Alternative Names: AIC; Amb a 1 Immunostimulatory Conjugate; TOLAMBALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Allergens; Antiallergics; DNA vaccines; Oligonucleotides; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 20 May 2008 Discontinued - Phase-II for Seasonal allergic rhinitis in Canada (SC)
- 24 Oct 2007 Phase-II clinical trials for Seasonal allergic rhinitis in Canada (SC)
- 08 Mar 2007 No development reported - Phase-II/III for Seasonal allergic rhinitis in Canada (SC)